MedTrace Logo

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

NCT00282048 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2012-07-31

Study results available
· View outcomes & findings →

Summary

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

Conditions

  • Kidney Neoplasms
  • Carcinoma, Renal Cell

Interventions

DRUG

AG-013736 (axitinib)

AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2009-02-28
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282048 on ClinicalTrials.gov